AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21842171 — intervention group
Group type: COMPARATOR
Intervention: neostigmine (0.04 mg/kg)
Number of subjects: 0
Study 19024312 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary static inflation with 1.0 MAC sevoflurane during CPB
Number of subjects: 60
Study 19024312 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary static inflation during CPB, no sevoflurane inhaled
Number of subjects: 60
Study 17074946 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated psychiatric advance directive session
Number of subjects: 469
Study 17074946 — intervention group
Group type: COMPARATOR
Intervention: Control group (written information about psychiatric advance directives and referral to resources)
Number of subjects: 469
Study 17074946 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 469
Study 12673181 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized meal of solid food and liquid (meal group)
Number of subjects: 60
Study 12673181 — intervention group
Group type: COMPARATOR
Intervention: No meal (control group)
Number of subjects: 60
Study 10755499 — intervention group
Group type: EXPERIMENTAL
Intervention: E5 (murine monoclonal antibody directed against endotoxin, 2 mg/kg per day by intravenous infusion 24 hours apart)
Number of subjects: 1090
Study 10755499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1090
Study 10755499 — intervention group
Group type: EXPERIMENTAL
Intervention: E5
Number of subjects: 1090
Study 10755499 — intervention group
Group type: EXPERIMENTAL
Intervention: E5 (in subgroup without shock)
Number of subjects: 1090
Study 10755499 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subgroup without shock)
Number of subjects: 1090
Study 8833987 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (400 micrograms i.v.)
Number of subjects: 11
Study 8833987 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (400 micrograms i.v.)
Number of subjects: 11
Study 8833987 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 11
Study 1421737 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms
Number of subjects: 22
Study 1421737 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 70 mg
Number of subjects: 22
Study 1421737 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid (placebo)
Number of subjects: 22
Study 3903786 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g triletide per day
Number of subjects: 20
Study 3903786 — intervention group
Group type: COMPARATOR
Intervention: 1.2 g cimetidine per day
Number of subjects: 20
Study 31639529 — intervention group
Group type: EXPERIMENTAL
Intervention: FORNET (adapted Narrative Exposure Therapy)
Number of subjects: 92
Study 31639529 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 92
Study 29274690 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 88
Study 29274690 — intervention group
Group type: COMPARATOR
Intervention: Healthy Eating diet
Number of subjects: 88
Study 26920597 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline eGFR >90
Number of subjects: 5244
Study 26920597 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline eGFR 60 to 90
Number of subjects: 5244
Study 26920597 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline eGFR 30 to 59
Number of subjects: 5244
Study 26920597 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline eGFR <30
Number of subjects: 5244
Study 26920597 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 5244
Study 24515764 — intervention group
Group type: EXPERIMENTAL
Intervention: H&E staining
Number of subjects: 441
Study 24515764 — intervention group
Group type: EXPERIMENTAL
Intervention: H&E plus p16INK4a staining
Number of subjects: 441
Study 22140123 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 57
Study 22140123 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 57
Study 20090545 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 189
Study 20090545 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir (LPV/r)
Number of subjects: 189
Study 18058305 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone %1 cream
Number of subjects: 90
Study 18058305 — intervention group
Group type: EXPERIMENTAL
Intervention: Unna's Boot cream
Number of subjects: 90
Study 18058305 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 90
Study 15851794 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa therapy
Number of subjects: 115
Study 12028390 — intervention group
Group type: EXPERIMENTAL
Intervention: Solo computer instruction (90 min of computer-guided solo instruction using 'FearFighter')
Number of subjects: 37
Study 12028390 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face small-group tutorial teaching (90 min)
Number of subjects: 37
Study 9802367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9802367 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 micro(g) once daily
Number of subjects: 20
Study 9802367 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 200 micro(g) once daily
Number of subjects: 20
Study 9802367 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA) 220 micro(g) once daily
Number of subjects: 20
Study 7713046 — intervention group
Group type: EXPERIMENTAL
Intervention: F2 (2.0 g/100 ml protein formula)
Number of subjects: 16
Study 7713046 — intervention group
Group type: COMPARATOR
Intervention: F1.5 (1.5 g/100 ml protein formula)
Number of subjects: 16
Study 2554715 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactovegetarian diet
Number of subjects: 0
Study 27203 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0
Study 27203 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0
Study 27203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30982113 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving Forward intervention trial (randomized, community-based, 6-month weight loss study)
Number of subjects: 210
Study 28259556 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin pour-on (Cydectin® 0.5% Pour-On, Zoetis) administered during the dry period (7–77 days before parturition) to 638 animals
Number of subjects: 1287
Study 28259556 — intervention group
Group type: COMPARATOR
Intervention: Untreated group of 649 animals
Number of subjects: 1287
Study 26012937 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin treatment in addition to calcium and vitamin D (Group I)
Number of subjects: 25
Study 26012937 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D only (Group II)
Number of subjects: 25
Study 23571802 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 7600
Study 23571802 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous irradiation therapy
Number of subjects: 7600
Study 23571802 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent seed implantation
Number of subjects: 7600
Study 23571802 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 7600
Study 22462232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganning formula (a Chinese herbal decoction)
Number of subjects: 150
Study 22462232 — intervention group
Group type: COMPARATOR
Intervention: Oral entecavir
Number of subjects: 150
Study 19198872 — intervention group
Group type: COMPARATOR
Intervention: Hypohydration -0% (EU)
Number of subjects: 8
Study 19198872 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydration -1% (H1)
Number of subjects: 8
Study 19198872 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydration -2% (H2)
Number of subjects: 8
Study 19198872 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydration -3% (H3)
Number of subjects: 8
Study 19198872 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydration severity
Number of subjects: 8
Study 19198872 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid controlling hormones (Antidiuretic hormone and aldosterone)
Number of subjects: 8
Study 19198872 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide
Number of subjects: 8
Study 16432056 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy (Warfarin or Aspirin)
Number of subjects: 569
Study 16432056 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe stenosis > or =70%
Number of subjects: 569
Study 16432056 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment within 17 days after qualifying event
Number of subjects: 569
Study 16432056 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 569
Study 15301617 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified visual search task with old and new objects preview
Number of subjects: 0
Study 15301617 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified displays in visual search task
Number of subjects: 0
Study 15301617 — intervention group
Group type: EXPERIMENTAL
Intervention: Outlines around distractor groups to aid segmentation
Number of subjects: 0
Study 15301617 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiment 4 ruling out spatial disengagement problems
Number of subjects: 0
Study 11587491 — intervention group
Group type: EXPERIMENTAL
Intervention: dl‐MPH‐IR after food
Number of subjects: 24
Study 11587491 — intervention group
Group type: EXPERIMENTAL
Intervention: dl‐MPH‐SR after food
Number of subjects: 24
Study 11587491 — intervention group
Group type: COMPARATOR
Intervention: dl‐MPH‐IR after fasting
Number of subjects: 24
Study 11587491 — intervention group
Group type: COMPARATOR
Intervention: dl‐MPH‐SR after fasting
Number of subjects: 24
Study 9045347 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin administered over 30 minutes and paclitaxel over 3 hours, every 4 weeks
Number of subjects: 83
Study 9045347 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel before carboplatin in ovarian cancer patients
Number of subjects: 83
Study 9045347 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing paclitaxel doses from 100 to 250 mg/m2
Number of subjects: 83
Study 9045347 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC and decrease in platelets
Number of subjects: 83
Study 9045347 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of carboplatin and paclitaxel
Number of subjects: 83
Study 7904761 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsapirone (10 mg to 30 mg daily)
Number of subjects: 90
Study 7904761 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam (2 mg to 6 mg daily)
Number of subjects: 90
Study 7904761 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study 3602267 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 30
Study 3602267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30765508 — intervention group
Group type: EXPERIMENTAL
Intervention: Omipalisib (0.25 mg, 1 mg, and 2 mg twice daily for 8 days)
Number of subjects: 17
Study 30765508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30073929 — intervention group
Group type: EXPERIMENTAL
Intervention: PEM therapy (Serrazyme and other constituents) for 2 months
Number of subjects: 450
Study 26873336 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 81
Study 26873336 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 81
Study 26873336 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (CT)
Number of subjects: 81
Study 24197970 — intervention group
Group type: EXPERIMENTAL
Intervention: ozonated oil‐zinc oxide
Number of subjects: 60
Study 24197970 — intervention group
Group type: COMPARATOR
Intervention: zinc oxide‐eugenol
Number of subjects: 60
Study 21601462 — intervention group
Group type: EXPERIMENTAL
Intervention: Extramedullary tibial instrumentation
Number of subjects: 56
Study 21601462 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary tibial instrumentation
Number of subjects: 56
Study 19770635 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (2000 mg/m/day for 14 days, once every 3 weeks) plus erlotinib (150 mg/day)
Number of subjects: 281
Study 19770635 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m as a 30-min infusion) plus erlotinib (150 mg/day)
Number of subjects: 281
Study 17351084 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) motor-tracking task
Number of subjects: 24
Study 16037756 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogen-containing supplement (soy isoflavones and Actaea racemosa)
Number of subjects: 124
Study 16037756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 11967598 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine‐chlorhexidine impregnated (SSC) catheters
Number of subjects: 90
Study 11967598 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver, platinum and carbon incorporated (SP+C) catheters
Number of subjects: 90
Study 11967598 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline and rifampin bonded (M+R) catheters
Number of subjects: 90
Study 11967598 — intervention group
Group type: COMPARATOR
Intervention: Non‐antiseptic central venous catheter segments
Number of subjects: 90
Study 10460765 — intervention group
Group type: EXPERIMENTAL
Intervention: Double patch with tape
Number of subjects: 435
Study 10460765 — intervention group
Group type: COMPARATOR
Intervention: No patch with tape
Number of subjects: 435
Study 8532911 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus hormone therapy
Number of subjects: 9
Study 8532911 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 9
Study 2092324 — intervention group
Group type: EXPERIMENTAL
Intervention: calcitonin (415 pmol i.v. bolus + continuous infusion during 90 min to reach an overall dose of 62.25 pmol.kg‐1 body mass)
Number of subjects: 8
Study 2092324 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 2092324 — intervention group
Group type: EXPERIMENTAL
Intervention: calcitonin
Number of subjects: 8
Study 353458 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg twice a day)
Number of subjects: 16
Study 353458 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg twice a day)
Number of subjects: 16
Study 353458 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone + alpha-methyldopa (250 mg three times a day)
Number of subjects: 16
Study 353458 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + alpha-methyldopa (250 mg three times a day)
Number of subjects: 16
Study 31870835 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum magnesium levels
Number of subjects: 3380
Study 31870835 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium–magnesium ratios
Number of subjects: 3380
Study 30509553 — intervention group
Group type: EXPERIMENTAL
Intervention: iCook 4-H treatment group
Number of subjects: 155
Study 30509553 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study 28439574 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 33
Study 28439574 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 33
Study 26399574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 1708
Study 26399574 — intervention group
Group type: EXPERIMENTAL
Intervention: Bordered polyurethane dressing
Number of subjects: 1708
Study 26399574 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless securement device
Number of subjects: 1708
Study 26399574 — intervention group
Group type: COMPARATOR
Intervention: Standard polyurethane dressing
Number of subjects: 1708
Study 24166518 — intervention group
Group type: EXPERIMENTAL
Intervention: N/F mutations (NOTCH1 and/or FBXW7)
Number of subjects: 212
Study 24166518 — intervention group
Group type: COMPARATOR
Intervention: No N/F mutations
Number of subjects: 212
Study 24166518 — intervention group
Group type: COMPARATOR
Intervention: K-RAS mutations
Number of subjects: 212
Study 24166518 — intervention group
Group type: COMPARATOR
Intervention: N-RAS mutations
Number of subjects: 212
Study 24166518 — intervention group
Group type: COMPARATOR
Intervention: PTEN mutations/deletions
Number of subjects: 212
Study 24166518 — intervention group
Group type: EXPERIMENTAL
Intervention: N/F mutations without RAS/PTEN abnormalities
Number of subjects: 212
Study 24166518 — intervention group
Group type: COMPARATOR
Intervention: N/F mutations with RAS/PTEN mutations
Number of subjects: 212
Study 24166518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncogenetic classifier
Number of subjects: 212
Study 20957601 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy (LP)
Number of subjects: 492
Study 20957601 — intervention group
Group type: COMPARATOR
Intervention: Open pyloromyotomy (OP)
Number of subjects: 492
Study 19040678 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release 1000 mg daily after initial 500 mg for 15 days
Number of subjects: 112
Study 17062029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse itraconazole (200 mg twice daily, 1 week on, 3 weeks off, for 12 weeks)
Number of subjects: 63
Study 17062029 — intervention group
Group type: COMPARATOR
Intervention: Continuous terbinafine (250 mg once daily for 12 weeks)
Number of subjects: 63
Study 14732756 — intervention group
Group type: EXPERIMENTAL
Intervention: 192-Iridium IRT
Number of subjects: 130
Study 11564447 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta4,16‐androstadien‐3‐one
Number of subjects: 65
Study 11564447 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,3,5,(10),16‐estratetraen‐3‐ol
Number of subjects: 65
Study 11564447 — intervention group
Group type: COMPARATOR
Intervention: Control (clove oil and propylene glycol)
Number of subjects: 65
Study 9610580 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral alprostadil therapy
Number of subjects: 452
Study 8138933 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms s.c.)
Number of subjects: 8
Study 8138933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3261548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg administered sublingually one minute before anaesthetic induction
Number of subjects: 30
Study 3261548 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nifedipine)
Number of subjects: 30
Study 3261548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine group
Number of subjects: 30
Study 31839571 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein/low carbohydrate low-calorie diet (Diet HP)
Number of subjects: 268
Study 31839571 — intervention group
Group type: COMPARATOR
Intervention: Standard low-calorie diet (Diet S)
Number of subjects: 268
Study 29496320 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-concentration-time points limited sampling model (0.5, 2, and 8 hours)
Number of subjects: 50
Study 29496320 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-concentration-time points limited sampling model (0.75, 2, and 8 hours)
Number of subjects: 50
Study 29496320 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-concentration-time points limited sampling model for saroglitazar sulfoxide
Number of subjects: 50
Study 28807988 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV (8 cm H2O inspiratory pressure, 4 cm H2O expiratory pressure, FIO2 0.5)
Number of subjects: 271
Study 28807988 — intervention group
Group type: COMPARATOR
Intervention: High-flow nasal cannula (flow 50 L/min, FIO2 0.5)
Number of subjects: 271
Study 28807988 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 271
Study 28807988 — intervention group
Group type: COMPARATOR
Intervention: High-flow nasal cannula
Number of subjects: 271
Study 25055809 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary gains
Number of subjects: 26
Study 25055809 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary penalties
Number of subjects: 26
Study 25055809 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment cortico-striatal connectivity
Number of subjects: 26
Study 23123099 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback during exercises
Number of subjects: 25
Study 23123099 — intervention group
Group type: COMPARATOR
Intervention: Exercise only (without EMG biofeedback)
Number of subjects: 25
Study 23123099 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 25
Study 22006106 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy for 5 weeks
Number of subjects: 83
Study 22006106 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control for 5 weeks
Number of subjects: 83
Study 18192493 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional knee brace
Number of subjects: 150
Study 18192493 — intervention group
Group type: COMPARATOR
Intervention: Neoprene sleeve
Number of subjects: 150
Study 16457716 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine patch
Number of subjects: 2500
Study 16457716 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine
Number of subjects: 2500
Study 14510796 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact-topical anaesthesia
Number of subjects: 100
Study 14510796 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar injection anaesthesia
Number of subjects: 100
Study 10761968 — intervention group
Group type: EXPERIMENTAL
Intervention: Education/feedback intervention program and patient awareness program
Number of subjects: 1575
Study 10761968 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based waterless hand antiseptic (1 dispenser for every 4 patients, then 1 for each patient)
Number of subjects: 1575
Study 8970271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone iontophoresis (1 ml of DEX at 4 mg/ml mixed with 1 ml of sterile water)
Number of subjects: 10
Study 8970271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone iontophoresis
Number of subjects: 10
Study 8970271 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 ml of saline solution)
Number of subjects: 10